<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janis E Blair, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Neil M Ampel, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2546007470"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Coccidioidomycosis is caused by the dimorphic fungus <em>Coccidioides. </em>Based on genomic analysis [<a href="#rid1">1</a>], it consists of two species, <em>Coccidioides immitis</em> and <em>Coccidioides posadasii</em>. However, these species are not distinguishable on either clinical presentation or through routine microbiologic testing. The fungus is endemic to certain regions of the Western Hemisphere, and infection is usually acquired by inhalation of airborne arthroconidia. Most cases are recognized as pulmonary infection, and infection beyond the thoracic cavity occurs in a small number of cases. An overview of the different manifestations of coccidioidomycosis is found in the table (<a class="graphic graphic_table graphicRef121586" href="/z/d/graphic/121586.html" rel="external">table 1</a>).</p><p>The manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis will be reviewed here. Primary pulmonary infection, laboratory diagnosis, pulmonary sequelae, coccidioidal meningitis, and management considerations, screening, and prevention in immunocompromised hosts and pregnant patients are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2420.html" rel="external">"Coccidioidomycosis: Laboratory diagnosis and screening"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2444.html" rel="external">"Management of pulmonary sequelae and complications of coccidioidomycosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2445.html" rel="external">"Coccidioidal meningitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients"</a>.)</p><p></p><p class="headingAnchor" id="H1158115328"><span class="h1">DEFINITION AND INCIDENCE OF DISSEMINATED INFECTIONS</span></p><p class="headingAnchor" id="H3513702035"><span class="h2">Definition of extrathoracic coccidioidomycosis</span><span class="headingEndMark"> — </span>Extrathoracic coccidioidomycosis is coccidioidal infection that is clinically apparent outside the thoracic cavity. Infection of the pleura or pleural space, as may occur in a ruptured coccidioidal cavity, is not considered disseminated disease. However, some clinicians feel that diffuse or reticulonodular pulmonary disease is a manifestation of dissemination since it is frequently associated with fungemia [<a href="#rid2">2</a>]. Extrapulmonary immunologic manifestations of primary pulmonary coccidioidomycosis, such as diffuse arthralgias or rashes, are also not considered manifestations of extrathoracic dissemination. (See  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection", section on 'Signs and symptoms'</a>.)</p><p class="headingAnchor" id="H577177719"><span class="h2">Incidence and risk factors for disseminated infection</span><span class="headingEndMark"> — </span>The risk of dissemination has been estimated to be 0.2 percent of all coccidioidal infections, including those with symptomatic and asymptomatic infection [<a href="#rid3">3</a>], but is likely higher in epidemic settings [<a href="#rid4">4</a>]. Patient groups at increased risk for extrathoracic dissemination include those who are:</p><p class="bulletIndent1"><span class="glyph">●</span>Of African or Filipino ancestry, particularly males</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnant females who contract coccidioidal infection during and after the second trimester</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Those who have suppressed cellular immunity, including (but not limited to) those with advanced human immunodeficiency virus (HIV) infection, transplant recipients, and those receiving chronic immunosuppressive medications such as glucocorticoids and anti-cytokine therapies (see  <a class="medical medical_review" href="/z/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients", section on 'Immunocompromised patients'</a>)</p><p></p><p class="headingAnchor" id="H1679386598"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>In most instances, extrathoracic dissemination appears to be the result of hematogenous spread of the organism and generally occurs early in the disease course. While there is also local lymphatic spread from pulmonary infection resulting in enlarged supraclavicular nodes, it is not established that this commonly results in disease outside the thorax [<a href="#rid5">5</a>]. Nevertheless, the fact that infection has spread to involve the supraclavicular region suggests exceptional progression of infection along the lymphatic chain, indicating that host defenses are not effectively limiting the infection to the lungs.</p><p class="headingAnchor" id="H3599661143"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H1392466350"><span class="h2">Spectrum of disease</span><span class="headingEndMark"> — </span>When extrathoracic dissemination occurs, it is usually evident within weeks to months after the initial exposure. Often, dissemination is clinically apparent at the time infection is first diagnosed [<a href="#rid6">6</a>]. In patients who do not receive treatment for early coccidioidal infection, disseminated disease occurring six or more months after initial infection is uncommon. However, in patients who have received early antifungal treatment, there are reports of delayed presentation of dissemination up to two years after treatment is stopped [<a href="#rid7">7</a>].</p><p>The nature of the symptoms depends upon the location and number of lesions. Although extrathoracic dissemination may affect nearly every organ system [<a href="#rid8">8</a>], the most common anatomic sites of disseminated lesions include skin and soft tissues, genital tract, peritoneum, and the central nervous system. In the immunocompromised host, extrathoracic disseminated coccidioidal lesions may occur more commonly and in less common anatomic sites, such as inguinal lymph nodes and the liver [<a href="#rid9">9,10</a>]. As an example, in renal transplant recipients without antifungal prophylaxis, approximately three-quarters of diagnosed infections result in extrathoracic lesions, more than 50-fold higher than in immunocompetent populations [<a href="#rid11">11</a>]. Patients with HIV and CD4 counts &lt;250 cells/microL can also present with fever and weight loss without any clear organ involvement in association with a positive coccidioidal serology [<a href="#rid12">12,13</a>]. </p><p>Symptoms of extrathoracic coccidioidomycosis may be indistinguishable from infection due to other granulomatous pathogens, cancer, or degenerative processes. Because of the indolent nature of the infection and lack of specificity of symptoms, the diagnosis of extrathoracic coccidioidomycosis is frequently delayed. This is especially true if the initial pulmonary infection has not been recognized.</p><p class="headingAnchor" id="H1657422157"><span class="h2">Skin and subcutaneous soft tissue</span><span class="headingEndMark"> — </span>Skin or subcutaneous soft tissue involvement includes cutaneous granulomatous lesions, subcutaneous soft tissue abscesses (<a class="graphic graphic_picture graphicRef110855" href="/z/d/graphic/110855.html" rel="external">picture 1</a>), and extrathoracic lymphadenopathy. Cutaneous coccidioidomycosis often presents with a persistent papule or verrucous lesion that may ulcerate. </p><p class="headingAnchor" id="H3331084037"><span class="h2">Bone and joints</span><span class="headingEndMark"> — </span><em>Coccidioides</em> spp can affect joints, tendons, as well as bone.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Joint and tendon involvement</strong> – Articular coccidioidomycosis is usually monoarticular and may involve any joint, although the knee is most commonly involved. It usually presents in a subacute manner, with persistent localized pain and swelling of the involved joint. Other commonly involved joints include the ankles, wrists, and hips. It may be associated with contiguous osteomyelitis. Arthrocentesis reveals a lymphocytic pleocytosis, and complement-fixation antibody titer is often higher than in serum. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone involvement</strong> – In one survey, the most common sites of coccidioidal osteomyelitis were the hand and wrist, pelvis, and knee [<a href="#rid14">14</a>]. Other sites include the elbow, calcaneum, and sternum, but any bone may be involved. Patients present with swelling and pain overlying the involved bone. In chronic cases, there may be development of a fistulous tract with purulent drainage. </p><p></p><p class="bulletIndent1">Infection of the axial skeleton is a special case. It usually involves the lumbar spine [<a href="#rid15">15</a>]. In contrast to bacterial vertebral osteomyelitis, infection generally begins within the vertebral body and without involvement of the end plate and adjacent disk space. In severe cases, axial coccidioidomycosis can result in vertebral collapse and nerve impingement. </p><p></p><p class="headingAnchor" id="H2918129237"><span class="h2">Genital tract</span><span class="headingEndMark"> — </span>In males, epididymal infection manifests as unilateral scrotal swelling, induration, and tenderness. Prostatic infection may present with urinary obstruction or prostatic tenderness. Occasionally, patients are asymptomatic and diagnosis is made incidentally during biopsy or surgical removal of the prostate. Female genital tract coccidioidomycosis is uncommon. It may present as a granulomatous endometritis, an adnexal mass, or as an extension of peritoneal disease [<a href="#rid16">16,17</a>].</p><p class="headingAnchor" id="H4215824800"><span class="h2">Peritoneum</span><span class="headingEndMark"> — </span>Coccidioidal infection to the peritoneum may occur through lymphatic spread rather than hematogenously. It usually presents with dull abdominal pain and increasing abdominal girth. An antecedent clinical history of pulmonary coccidioidomycosis occurs in fewer than half of the patients [<a href="#rid10">10</a>]. Imaging frequently reveals ascites with a thickened peritoneum, similar to peritoneal carcinomatosis or peritoneal tuberculosis [<a href="#rid18">18</a>]. </p><p class="headingAnchor" id="H2868167876"><span class="h2">Central nervous system</span><span class="headingEndMark"> — </span>Of all sites of dissemination, meningitis is the most uniformly serious and poses special problems in management. It is addressed separately. (See  <a class="medical medical_review" href="/z/d/html/2445.html" rel="external">"Coccidioidal meningitis"</a>.)</p><p class="headingAnchor" id="H2869638481"><span class="h2">Other sites</span><span class="headingEndMark"> — </span>Other less frequent sites of dissemination include the eye [<a href="#rid19">19-21</a>] and the pericardium [<a href="#rid22">22</a>], but almost any anatomic site may be involved [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H2037922085"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H1759325437"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>For patients with suspected extrathoracic coccidioidomycosis, the initial evaluation includes serologic testing and imaging of clinically suspicious areas. Although less sensitive than antibody testing, obtaining serum or urine antigen may also be useful in this situation to help add to diagnostic certainty when biopsy is either unable to be performed or is negative for coccidioides (<a class="graphic graphic_table graphicRef121586" href="/z/d/graphic/121586.html" rel="external">table 1</a>) [<a href="#rid24">24-26</a>]. A detailed discussion of diagnostic testing is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2420.html" rel="external">"Coccidioidomycosis: Laboratory diagnosis and screening", section on 'Diagnostic tests'</a>.)</p><p>We image specific anatomic sites as directed by history or findings on clinical examination. Computed tomography (CT) scan and magnetic resonance imaging (MRI) are preferred imaging modalities although positron emission tomography (PET)/CT can also identify sites of dissemination [<a href="#rid27">27</a>]. MRI with gadolinium enhancement can be especially helpful in defining the extent of individual lesions in vertebral osteomyelitis [<a href="#rid28">28</a>]. The role of performing imaging in persons without clinically evident dissemination is unclear. </p><p class="headingAnchor" id="H2947570755"><span class="h2">Confirming the diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of disseminated coccidioidomycosis should be confirmed by identifying <em>Coccidioides </em>spp in one or more sites outside the thoracic cavity, either by visualizing spherules in histopathology specimens or by culture of a lesion in the affected organ. </p><p>A possible exception to obtaining tissue is when the lesions are deemed too difficult or too unsafe for biopsy and the patient has demonstrable destructive lesions on imaging and positive coccidioidal serologic results; in such situations, empiric treatment for nonconfirmed infection must be monitored to assure efficacy. </p><p>An elevated complement-fixing antibody titer without demonstrable extrathoracic lesions is not sufficient to diagnose disseminated infection, as it can often be seen in pulmonary coccidioidal disease [<a href="#rid29">29</a>]. Because of this, the diagnosis of extrathoracic disseminated coccidioidomycosis depends on identification of <em>Coccidioides</em> spp outside of the thoracic cavity. (See  <a class="medical medical_review" href="/z/d/html/2420.html" rel="external">"Coccidioidomycosis: Laboratory diagnosis and screening", section on 'Recovery of Coccidioides from clinical specimens'</a>.)</p><p class="headingAnchor" id="H3620395218"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The management of nonpregnant patients with nonmeningeal extrathoracic infection will be reviewed here. Special considerations regarding the management of pregnant females and immunocompromised individuals are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients", section on 'Management considerations for special populations'</a>.)</p><p class="headingAnchor" id="H2965530965"><span class="h2">Approach to treatment</span><span class="headingEndMark"> — </span>Nearly all patients with disseminated infections should be treated with antifungal therapy; an exception may be children with isolated skin lesions, although any decisions not to treat should be made after consultation with a pediatric infectious disease specialist familiar with managing coccidioidal disease. Surgical debridement or stabilization may be critical as adjunctive treatment in some cases, particularly when there is vertebral involvement. If left untreated, patients can develop severe infection, including limb-threatening skeletal disease, vertebral infection causing cord compromise, and airway obstruction due to paratracheal abscess. (See <a class="local">'Determining the need for surgery'</a> below.). </p><p class="headingAnchor" id="H1992754068"><span class="h3">Mild to moderate disease</span><span class="headingEndMark"> — </span>For patients with extrathoracic nonmeningeal coccidioidomycosis who are clinically stable and do not have lesions that pose an emergency, we suggest the use of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> or <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>. Other triazole antifungals, such as <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, and <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">isavuconazole</a>, may be useful in patients who cannot tolerate the recommended azole agents and in those who have refractory disease that is neither rapid nor life threatening. </p><p>The choice of triazole depends upon many issues, including the site of infection, cost, availability, adverse effects, and drug-drug interactions. Because of this, all triazole antifungal agents are appropriate therapy and we cannot recommend one over another at this time. The triazole dose and duration of therapy depend upon the site of infection. (See <a class="local">'Issues related to certain clinical manifestations'</a> below.)</p><p>Early prospective studies support the use of either <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> or <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> [<a href="#rid30">30,31</a>]. However, data from a comparative trial comparing fluconazole to itraconazole for nonmeningeal coccidioidomycosis suggest that patients who received itraconazole may have a higher response rate compared with fluconazole (63 versus 50 percent), especially in the setting of bone and joint disease (52 versus 26 percent). Moreover, relapse rates after discontinuation were lower but not statistically significant with itraconazole compared with fluconazole (18 versus 28 percent) [<a href="#rid32">32</a>]. However, the potential improved efficacy should be tempered with other issues. Itraconazole is not routinely absorbed in all patients, making a serum level imperative. In addition, its use may be associated with hypokalemia and hypertension [<a href="#rid33">33</a>], as well as decreased cardiac inotropy [<a href="#rid34">34</a>]. There may also be cost and insurance considerations. Additional considerations, such as increased risk for drug interactions, are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Drug interactions'</a>.)</p><p>There is less experience with the newer triazole antifungals <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> and <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">isavuconazole</a>. However, both voriconazole and posaconazole appear to be effective in patients who fail to respond to other either <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> or <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> therapy [<a href="#rid35">35</a>]. An older formulation of posaconazole was shown to produce both complete and partial responses in patients who were refractory to prior antifungal therapy [<a href="#rid36">36</a>]. The newer delayed release posaconazole formulation also appears to be effective. Similarly, a study of isavuconazole, conjugated as isavuconazonium, demonstrated efficacy in refractory cases of nonmeningeal coccidioidomycosis [<a href="#rid37">37</a>].</p><p>There are no trials comparing amphotericin B with triazole antifungal therapy. The decision to use a triazole rather than amphotericin B for patients with mild extrathoracic disease is based upon the observed efficacy of these agents and their reduced toxicity compared with amphotericin B. </p><p>A more detailed discussion of the different azoles is found in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles"</a>.)</p><p class="headingAnchor" id="H3000373049"><span class="h3">Severe or refractory disease</span><span class="headingEndMark"> — </span>For patients with severe extrathoracic nonmeningeal coccidioidomycosis (eg, clinically unstable, rapidly progressive disease, lesions in critical anatomic locations such as the spine) or those who have not improved with azole therapy, we suggest <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> along with a triazole antifungal. Although the combination of amphotericin B plus triazoles has been suggested to be antagonistic for some fungal infections [<a href="#rid38">38</a>], this is not the case in candidiasis [<a href="#rid39">39</a>] and not the clinical experience in coccidioidomycosis. Because of this, we advocate using the combination in cases of severe coccidioidomycosis. Once the patient is clinically improving (usually after one to three weeks of therapy), we transition to triazole monotherapy. (See <a class="local">'Mild to moderate disease'</a> above.) </p><p>There are no trials comparing amphotericin B with triazole antifungal therapy. The use of amphotericin B in combination with a triazole for more severe disease is based upon expert opinion that amphotericin B may exert an antifungal effect more quickly. There are no comparative trials of deoxycholate amphotericin B versus lipid formulations for the treatment of coccidioidomycosis, and either formulation is appropriate. However, there is an emerging preference to use <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> because of reduced renal toxicity [<a href="#rid40">40</a>] and evidence of increased efficacy in other fungal infections [<a href="#rid41">41,42</a>]. Trials in patients with HIV-1 infection and cryptococcosis [<a href="#rid43">43</a>] and histoplasmosis [<a href="#rid44">44</a>] have suggested that a single dose of 10 mg/kg liposomal amphotericin B is not inferior to standard courses of liposomal amphotericin B. There are no data regarding this in coccidioidomycosis and it is not currently recommended.</p><p>Because cellular immunity is important in the immune control of coccidioidal infection, there has been interest in using interferon gamma for patients with disseminated infection or other serious complications. Although case reports suggest the use of interferon gamma, alone or in combination with other immunomodulatory agents, may lead to clinical improvement [<a href="#rid45">45-47</a>], the efficacy of this approach has not been generally established. </p><p>Management aspects specific to immunocompromised and/or pregnant individuals are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients", section on 'Management considerations for special populations'</a>.)</p><p class="headingAnchor" id="H301281747"><span class="h2">Issues related to certain clinical manifestations</span><span class="headingEndMark"> — </span>Because of the diversity of possible locations and severity of coccidioidal lesions, guidelines cannot address all the various situations that might be seen. The following specific examples have been commonly encountered by clinicians practicing within the endemic area and provide illustrative examples of treatment approaches.</p><p class="headingAnchor" id="H645323024"><span class="h3">Soft tissue infection without bone involvement</span><span class="headingEndMark"> — </span>An oral triazole antifungal (<a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> 400 mg once daily or <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> 200 mg twice daily with food) is appropriate for most patients with skin and soft tissue infection. The duration of treatment is generally 6 to 12 months but may be longer, especially in immunocompromised individuals. Relapses after therapy can occur. (See <a class="local">'Risk of relapse after treatment'</a> below.) </p><p class="headingAnchor" id="H1887984339"><span class="h3">Bone and joint infection</span></p><p class="headingAnchor" id="H371650456"><span class="h4">Antifungal therapy</span><span class="headingEndMark"> — </span>All patients with bone and joint infection require antifungal therapy. In addition, certain patients with vertebral disease may require surgical intervention. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild to moderate bone and/or joint disease </strong>– For patients with nonsevere bone and/or joint disease, an oral triazole antifungal (preferably <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>) is appropriate. Data suggest that itraconazole (200 mg twice daily with food) may be superior to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> in this setting. In a study of 50 patients with coccidioidal bone and/or joint infection, 52 percent of patients receiving itraconazole had clinical response to therapy compared with 26 percent of patients receiving fluconazole, although the difference was not statistically significant [<a href="#rid32">32</a>]. Moreover, relapse rates after discontinuation were lower for itraconazole. If fluconazole is used, some experts recommend doses higher than 400 mg daily (eg, 800 mg once daily), although data are lacking to support this recommendation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe bone and/or joint disease </strong>– For patients with severe bone and/or joint disease, such as limb-threatening skeletal disease or vertebral infection causing imminent cord compromise, we initiate amphotericin B plus a triazole antifungal (eg, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> 200 mg orally twice daily). We prefer a lipid formulation, such as <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> at 5 mg/kg intravenously per day. We administer amphotericin B therapy daily for at least 10 days. After that, the dose of amphotericin B can be reduced to three times weekly. We continue that dose until the most serious lesions have started to improve. </p><p></p><p class="bulletIndent1">The triazole agent should be continued after the course of amphotericin B is completed. The duration of antifungal treatment for patients with bone and joint infections is prolonged and should be individualized based on response to therapy. Courses of treatment with triazole antifungals are usually continued for months to years and, in some cases, are lifelong since relapse following the discontinuation of treatment can never be excluded. (See <a class="local">'Risk of relapse after treatment'</a> below.)</p><p></p><p class="bulletIndent1">We combine a triazole antifungal (eg, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> 200 mg orally twice daily) with the amphotericin B, unless pharmacologic factors or untoward reactions weigh against that choice. Based on clinical observations, combined therapy with a triazole and amphotericin B appears to speed recovery and simplify the transition to triazole therapy alone. There is no evidence for antagonism in this situation.</p><p></p><p class="headingAnchor" id="H2082873147"><span class="h4">Determining the need for surgery</span><span class="headingEndMark"> — </span>For patients with bone and joint infection, optimal management may require combined medical and surgical interventions. However, it is frequently difficult to determine the need for surgery. Examples of our approach in certain settings include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monoarticular arthritis</strong> – Monoarticular arthritis can be an unexpected diagnosis at the time of arthroscopy. The infection may be limited completely to the synovium, and in such cases, antifungal treatment without surgical intervention is often quite effective in completely resolving the signs and symptoms of infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vertebral osteomyelitis</strong> – We obtain orthopedic or neurosurgical consultation for most patients with vertebral coccidioidal infection to help assess the need for surgical intervention. The management of these lesions is especially important because of their potential impact on the spinal cord and mobility. For those with evidence of cord impingement, immediate surgical decompression is usually recommended. </p><p></p><p class="bulletIndent1">Patients who do not require initial surgery should be followed closely on treatment. Subsequent management depends upon the evolution of lesions as evidenced by symptoms, neurologic examination, and repeated MRI, which should generally be obtained within one or two months. For progressive lesions, surgical options are reconsidered. For those that are stable or show improvement, medical management alone is continued with repeated MRI at progressively longer intervals. </p><p></p><p class="headingAnchor" id="H262655392"><span class="h3">Supraclavicular lymphadenopathy</span><span class="headingEndMark"> — </span>We treat supraclavicular adenopathy with an oral triazole antifungal (<a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> 400 mg once daily or <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> 200 mg twice daily with food) for 6 to 12 months. Although lymphadenopathy usually resolves with antifungal therapy, surgical resection may be required in some cases. Relapses after therapy can occur.</p><p class="headingAnchor" id="H4062340685"><span class="h3">Prostatic infection</span><span class="headingEndMark"> — </span>For patients with prostatic infection, the approach to treatment depends upon how the infection is identified.</p><p>For asymptomatic patients who are diagnosed using serology or fine-needle biopsy, we typically follow them without treatment and monitor them with periodic office visits and coccidioidal serologies yearly or twice yearly. Generally, these prostatic lesions do not become symptomatic, and the patients do not go on to develop new lesions elsewhere.</p><p>If coccidioidal involvement of the prostate is discovered as the result of a transurethral or radical prostatectomy, the greater anatomic disruption by these procedures compared with a fine-needle biopsy greatly increases the risk of subsequent complications from the infection. In these situations, antifungal therapy with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (400 mg daily) or <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> (200 mg twice daily) is appropriate [<a href="#rid48">48</a>]. Duration of therapy should be at least 6 months in immunocompetent patients and at least 12 months in immunocompromised patients. Decision to stop treatment should be directed by change in serologic titer.</p><p>In contrast to the above, patients presenting with clinical symptoms of genital tract involvement (eg, prostatitis, testicular or epididymal swelling) require prolonged courses of triazole antifungal therapy [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H3826216900"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>We monitor patients every 12 weeks with clinical evaluation, appropriate imaging, and the complement-fixation titer for the duration of therapy and for at least one to two years after treatment has completed [<a href="#rid50">50</a>]. The complement-fixation titer is an important tool in assessing response to treatment; an increasing titer suggests increasingly active disease. (See <a class="local">'Risk of relapse after treatment'</a> below.)</p><p>Patients should also be monitored for toxicity related to antifungal therapy, and those receiving <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, and <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> should have therapeutic drug monitoring. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Serum drug concentration monitoring'</a>.)</p><p class="headingAnchor" id="H2658327611"><span class="h2">Risk of relapse after treatment</span><span class="headingEndMark"> — </span>Antifungal agents suppress but do not eradicate coccidioidal infection; thus, there is potential for relapse once treatment is discontinued in patients who respond to therapy. In the trial comparing <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> and <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> treatment described above, relapse rates following the completion of 12 months of therapy were 28 and 18 percent, respectively [<a href="#rid32">32</a>]. However, these relapse rates are likely underestimates, because many treating providers were unwilling to stop treatment at the end of the study.</p><p>Almost all relapses occur at the site of previously identified lesions rather than at new sites. Although it is reasonable to discontinue therapy at least once for most patients with nonmeningeal coccidioidomycosis, some clinicians elect to continue treatment indefinitely if the site of the initial lesion is particularly critical, because a repeat recurrence, even if detected early, might be deleterious to the patient. In some instances, surgical extirpation of a focus of coccidioidal infection may prevent subsequent relapses. (See <a class="local">'Bone and joint infection'</a> above.) </p><p>Certain immunocompromised hosts (eg, transplant recipients who remain on immunosuppressive therapy) may require antifungal therapy indefinitely. Additional information on the management of immunocompromised hosts is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients", section on 'Secondary prevention'</a>.) </p><p class="headingAnchor" id="H1848596171"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113064.html" rel="external">"Society guideline links: Coccidioidomycosis"</a>.)</p><p class="headingAnchor" id="H3231557334"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (See  <a class="medical medical_basics" href="/z/d/html/87358.html" rel="external">"Patient education: Valley Fever (coccidioidomycosis) (The Basics)"</a>.) </p><p></p><p class="headingAnchor" id="H688495182"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and incidence of disseminated infections </strong>–<strong> </strong>Extrathoracic coccidioidomycosis is coccidioidal infection that is clinically apparent outside the thoracic cavity. The risk of dissemination is low, but certain groups are at increased risk (eg, immunocompromised individuals, pregnant individuals in their second or third trimester, and those of African or Filipino descent). (See <a class="local">'Introduction'</a> above and <a class="local">'Definition and incidence of disseminated infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>–<strong> </strong>Infection is usually acquired by inhalation, causing primary pulmonary infection. Dissemination of infection beyond the thoracic cavity may occur. Extrathoracic dissemination is usually the result of hematogenous spread. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> –<strong> </strong>Disseminated infection frequently becomes evident within weeks and usually within six months after the initial exposure if antifungal therapy has not been given. The most common sites of disseminated lesions are skin, subcutaneous soft tissue, meninges, and skeleton. (See <a class="local">'Clinical manifestations'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>–<strong> </strong>For patients with suspected extrathoracic coccidioidomycosis, the initial evaluation includes serologic testing and imaging of suspected areas. Serum or urine antigen testing may also be helpful. The diagnosis of disseminated infection should almost always be confirmed with a biopsy demonstrating evidence of <em>Coccidioides</em> spp outside the chest. (See <a class="local">'Diagnosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antifungal therapy </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild to moderate disease</strong> –<strong> </strong>For nonpregnant patients who present with extrathoracic nonmeningeal coccidioidomycosis and are without lesions that pose an emergency, we suggest initial therapy with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> or <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> rather than amphotericin B (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Itraconazole may have some advantage over fluconazole, especially in the setting of bone and joint disease. However, data are limited, and the potential improved efficacy has to be tempered with other issues, such as drug interactions and the need to monitor drug levels. (See <a class="local">'Mild to moderate disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe disease</strong> – For nonpregnant patients who present with rapidly progressive disease or lesions that could cause significant organ compromise, we suggest combination therapy with amphotericin B plus a triazole (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Once the patient is clinically stable, amphotericin B can be stopped and triazole monotherapy continued for the rest of the treatment duration. (See <a class="local">'Severe or refractory disease'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive surgical intervention</strong> –<strong> </strong>Most patients with nonmeningeal extrathoracic coccidioidomycosis can be treated with antifungal therapy alone. However, for certain patients (eg, those with vertebral involvement causing cord compression), surgical debridement or stabilization may be important as adjunctive treatment. (See <a class="local">'Determining the need for surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> –<strong> </strong>The duration of therapy depends upon the site of infection. Treatment can range from 6 to 12 months for soft tissue infections to lifelong therapy if the site of the initial lesion is particularly critical. (See <a class="local">'Management'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring and risk of relapse</strong> –<strong> </strong>Monitoring of the complement-fixation titer is an important tool in assessing response to treatment. In general, this test should be repeated about every 12 weeks while on therapy. Serologic monitoring should continue for at least one year if antifungal therapy is stopped, since there is potential for relapse once treatment is discontinued. (See <a class="local">'Monitoring'</a> above and <a class="local">'Risk of relapse after treatment'</a> above.) </p><p></p><p class="headingAnchor" id="H1536779778"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges John Galgiani, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fisher MC, Koenig GL, White TJ, Taylor JW. Molecular and phenotypic description of Coccidioides posadasii sp. nov., previously recognized as the non-California population of Coccidioides immitis. Mycologia 2002; 94:73.</a></li><li><a class="nounderline abstract_t">Ampel NM, Ryan KJ, Carry PJ, et al. Fungemia due to Coccidioides immitis. An analysis of 16 episodes in 15 patients and a review of the literature. Medicine (Baltimore) 1986; 65:312.</a></li><li><a class="nounderline abstract_t">Barnato AE, Sanders GD, Owens DK. Cost-effectiveness of a potential vaccine for Coccidioides immitis. Emerg Infect Dis 2001; 7:797.</a></li><li><a class="nounderline abstract_t">Flynn NM, Hoeprich PD, Kawachi MM, et al. An unusual outbreak of windborne coccidioidomycosis. N Engl J Med 1979; 301:358.</a></li><li><a class="nounderline abstract_t">Mayer AP, Morris MF, Panse PM, et al. Does the presence of mediastinal adenopathy confer a risk for disseminated infection in immunocompetent persons with pulmonary coccidioidomycosis? Mycoses 2013; 56:145.</a></li><li><a class="nounderline abstract_t">Bays DJ, Thompson GR, Reef S, et al. Natural History of Disseminated Coccidioidomycosis: Examination of the Veterans Affairs-Armed Forces Database. Clin Infect Dis 2021; 73:e3814.</a></li><li><a class="nounderline abstract_t">Ampel NM, Giblin A, Mourani JP, Galgiani JN. Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis. Clin Infect Dis 2009; 48:172.</a></li><li><a class="nounderline abstract_t">Adam RD, Elliott SP, Taljanovic MS. The spectrum and presentation of disseminated coccidioidomycosis. Am J Med 2009; 122:770.</a></li><li><a class="nounderline abstract_t">Fish DG, Ampel NM, Galgiani JN, et al. Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. Medicine (Baltimore) 1990; 69:384.</a></li><li><a class="nounderline abstract_t">Johnson RH, Sharma R, Sharma R, et al. Coccidioidal Peritonitis: A Review of 17 Cases. Open Forum Infect Dis 2022; 9:ofac017.</a></li><li><a class="nounderline abstract_t">Cohen IM, Galgiani JN, Potter D, Ogden DA. Coccidioidomycosis in renal replacement therapy. Arch Intern Med 1982; 142:489.</a></li><li><a class="nounderline abstract_t">Arguinchona HL, Ampel NM, Dols CL, et al. Persistent coccidioidal seropositivity without clinical evidence of active coccidioidomycosis in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 20:1281.</a></li><li><a class="nounderline abstract_t">Ampel NM. Coccidioidomycosis in persons infected with HIV type 1. Clin Infect Dis 2005; 41:1174.</a></li><li><a class="nounderline abstract_t">Ricciotti RW, Shekhel TA, Blair JE, et al. Surgical pathology of skeletal coccidioidomycosis: a clinical and histopathologic analysis of 25 cases. Am J Surg Pathol 2014; 38:1672.</a></li><li><a class="nounderline abstract_t">Szeyko LA, Taljanovic MS, Dzioba RB, et al. Vertebral coccidioidomycosis: presentation and multidisciplinary management. Am J Med 2012; 125:304.</a></li><li><a class="nounderline abstract_t">Saw EC, Shields SJ, Comer TP, Huntington RW Jr. Granulomatous peritonitis due to Coccidioides immitis. Arch Surg 1974; 108:369.</a></li><li><a class="nounderline abstract_t">Bylund DJ, Nanfro JJ, Marsh WL Jr. Coccidioidomycosis of the female genital tract. Arch Pathol Lab Med 1986; 110:232.</a></li><li><a class="nounderline abstract_t">Storage TR, Segal J, Brown J. Peritoneal Coccidioidomycosis: a Rare Case Report and Review of the Literature. J Gastrointestin Liver Dis 2015; 24:527.</a></li><li><a class="nounderline abstract_t">Rodenbiker HT, Ganley JP. Ocular coccidioidomycosis. Surv Ophthalmol 1980; 24:263.</a></li><li><a class="nounderline abstract_t">Ling JJ, Bays DJ, Thompson GR 3rd, et al. Favorable Outcome in Coccidioides Endophthalmitis-A Combined Medical and Surgical Treatment Approach. Cornea 2017; 36:1423.</a></li><li><a class="nounderline abstract_t">Ahmad TR, Li J, Wu F, et al. COCCIDIOIDAL ENDOPHTHALMITIS: EXCELLENT RECOVERY OF VISION WITH AGGRESSIVE USE OF INTRAVITREAL ANTIFUNGALS AND VITRECTOMY. Retin Cases Brief Rep 2022; 16:523.</a></li><li><a class="nounderline abstract_t">Chan O, Low SW, Urcis R, et al. Coccidioidomycosis with Pericardial Involvement: Case Report and Literature Review. Am J Med 2016; 129:e21.</a></li><li class="breakAll">Stevens DA. Other Coccidioidal Syndromes. In: Coccidioidomycosis. A Text., Stevens DA (Ed), Plenum Publishing Corporation, New York 1980. p.237.</li><li><a class="nounderline abstract_t">Durkin M, Connolly P, Kuberski T, et al. Diagnosis of coccidioidomycosis with use of the Coccidioides antigen enzyme immunoassay. Clin Infect Dis 2008; 47:e69.</a></li><li><a class="nounderline abstract_t">Durkin M, Estok L, Hospenthal D, et al. Detection of Coccidioides antigenemia following dissociation of immune complexes. Clin Vaccine Immunol 2009; 16:1453.</a></li><li><a class="nounderline abstract_t">Kassis C, Durkin M, Holbrook E, et al. Advances in Diagnosis of Progressive Pulmonary and Disseminated Coccidioidomycosis. Clin Infect Dis 2021; 72:968.</a></li><li><a class="nounderline abstract_t">Foerter J, Sundell J, Vroman P. PET/CT: First-Line Examination to Assess Disease Extent of Disseminated Coccidioidomycosis. J Nucl Med Technol 2016; 44:212.</a></li><li><a class="nounderline abstract_t">Erly WK, Bellon RJ, Seeger JF, Carmody RF. MR imaging of acute coccidioidal meningitis. AJNR Am J Neuroradiol 1999; 20:509.</a></li><li><a class="nounderline abstract_t">McHardy IH, Dinh BN, Waldman S, et al. Coccidioidomycosis Complement Fixation Titer Trends in the Age of Antifungals. J Clin Microbiol 2018; 56.</a></li><li><a class="nounderline abstract_t">Catanzaro A, Fierer J, Friedman PJ. Fluconazole in the treatment of persistent coccidioidomycosis. Chest 1990; 97:666.</a></li><li><a class="nounderline abstract_t">Graybill JR, Stevens DA, Galgiani JN, et al. Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group. Am J Med 1990; 89:282.</a></li><li><a class="nounderline abstract_t">Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med 2000; 133:676.</a></li><li><a class="nounderline abstract_t">Hoffmann WJ, McHardy I, Thompson GR 3rd. Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation. Mycoses 2018; 61:337.</a></li><li><a class="nounderline abstract_t">Paul V, Rawal H. Cardiotoxicity with Itraconazole. BMJ Case Rep 2017; 2017.</a></li><li><a class="nounderline abstract_t">Kim MM, Vikram HR, Kusne S, et al. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis 2011; 53:1060.</a></li><li><a class="nounderline abstract_t">Stevens DA, Rendon A, Gaona-Flores V, et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007; 132:952.</a></li><li><a class="nounderline abstract_t">Thompson GR 3rd, Rendon A, Ribeiro Dos Santos R, et al. Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. Clin Infect Dis 2016; 63:356.</a></li><li><a class="nounderline abstract_t">Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995; 39:1907.</a></li><li><a class="nounderline abstract_t">Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36:1221.</a></li><li><a class="nounderline abstract_t">Sidhu R, Lash DB, Heidari A, et al. Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002; 137:105.</a></li><li><a class="nounderline abstract_t">Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis 2010; 51:225.</a></li><li><a class="nounderline abstract_t">Jarvis JN, Lawrence DS, Meya DB, et al. Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. N Engl J Med 2022; 386:1109.</a></li><li><a class="nounderline abstract_t">Pasqualotto AC, Lana DD, Godoy CSM, et al. Single High Dose of Liposomal Amphotericin B in Human Immunodeficiency Virus/AIDS-Related Disseminated Histoplasmosis: A Randomized Trial. Clin Infect Dis 2023; 77:1126.</a></li><li><a class="nounderline abstract_t">Duplessis CA, Tilley D, Bavaro M, et al. Two cases illustrating successful adjunctive interferon-γ immunotherapy in refractory disseminated coccidioidomycosis. J Infect 2011; 63:223.</a></li><li><a class="nounderline abstract_t">Arbeloa-Gutierrez L, Kuberski T, Johnson SM, et al. Reactivation of coccidioidomycosis: a prosthetic joint infection in Spain. Eur J Clin Microbiol Infect Dis 2016; 35:183.</a></li><li><a class="nounderline abstract_t">Tsai M, Thauland TJ, Huang AY, et al. Disseminated Coccidioidomycosis Treated with Interferon-γ and Dupilumab. N Engl J Med 2020; 382:2337.</a></li><li><a class="nounderline abstract_t">Yurkanin JP, Ahmann F, Dalkin BL. Coccidioidomycosis of the prostate: a determination of incidence, report of 4 cases, and treatment recommendations. J Infect 2006; 52:e19.</a></li><li><a class="nounderline abstract_t">Sohail MR, Andrews PE, Blair JE. Coccidioidomycosis of the male genital tract. J Urol 2005; 173:1978.</a></li><li><a class="nounderline abstract_t">Pappagianis D. Serologic studies in coccidioidomycosis. Semin Respir Infect 2001; 16:242.</a></li></ol></div><div id="topicVersionRevision">Topic 2449 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21156479" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Molecular and phenotypic description of Coccidioides posadasii sp. nov., previously recognized as the non-California population of Coccidioides immitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3528738" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Fungemia due to Coccidioides immitis. An analysis of 16 episodes in 15 patients and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11747691" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cost-effectiveness of a potential vaccine for Coccidioides immitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/460324" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : An unusual outbreak of windborne coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22809175" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Does the presence of mediastinal adenopathy confer a risk for disseminated infection in immunocompetent persons with pulmonary coccidioidomycosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32778863" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Natural History of Disseminated Coccidioidomycosis: Examination of the Veterans Affairs-Armed Forces Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19072555" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19635278" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The spectrum and presentation of disseminated coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2146461" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35169589" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Coccidioidal Peritonitis: A Review of 17 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7039544" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Coccidioidomycosis in renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7620011" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Persistent coccidioidal seropositivity without clinical evidence of active coccidioidomycosis in patients infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16163637" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Coccidioidomycosis in persons infected with HIV type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25007149" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Surgical pathology of skeletal coccidioidomycosis: a clinical and histopathologic analysis of 25 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22340929" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Vertebral coccidioidomycosis: presentation and multidisciplinary management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4273212" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Granulomatous peritonitis due to Coccidioides immitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3753858" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Coccidioidomycosis of the female genital tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26697582" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Peritoneal Coccidioidomycosis: a Rare Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6988997" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Ocular coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28872517" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Favorable Outcome in Coccidioides Endophthalmitis-A Combined Medical and Surgical Treatment Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32541432" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : COCCIDIOIDAL ENDOPHTHALMITIS: EXCELLENT RECOVERY OF VISION WITH AGGRESSIVE USE OF INTRAVITREAL ANTIFUNGALS AND VITRECTOMY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26642905" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Coccidioidomycosis with Pericardial Involvement: Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26642905" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Coccidioidomycosis with Pericardial Involvement: Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18781884" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diagnosis of coccidioidomycosis with use of the Coccidioides antigen enzyme immunoassay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19675225" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Detection of Coccidioides antigenemia following dissociation of immune complexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32108231" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Advances in Diagnosis of Progressive Pulmonary and Disseminated Coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27102664" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : PET/CT: First-Line Examination to Assess Disease Extent of Disseminated Coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10219420" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : MR imaging of acute coccidioidal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30257902" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Coccidioidomycosis Complement Fixation Titer Trends in the Age of Antifungals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2306969" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fluconazole in the treatment of persistent coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2168126" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11074900" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29385285" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28400399" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cardiotoxicity with Itraconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22045955" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Treatment of refractory coccidioidomycosis with voriconazole or posaconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17573510" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Posaconazole therapy for chronic refractory coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27169478" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8540690" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Use of amphotericin B with azole antifungal drugs: what are we doing?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12746765" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29686150" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12118965" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20536366" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35320642" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37232940" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Single High Dose of Liposomal Amphotericin B in Human Immunodeficiency Virus/AIDS-Related Disseminated Histoplasmosis: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791226" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Two cases illustrating successful adjunctive interferon-γimmunotherapy in refractory disseminated coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26638217" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Reactivation of coccidioidomycosis: a prosthetic joint infection in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32521134" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Disseminated Coccidioidomycosis Treated with Interferon-γand Dupilumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15936822" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Coccidioidomycosis of the prostate: a determination of incidence, report of 4 cases, and treatment recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15879796" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Coccidioidomycosis of the male genital tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11740825" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Serologic studies in coccidioidomycosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
